Astrana Health (ASTH) stock soared 5.45% in a day, demonstrating investor optimism despite mixed second-quarter results for 2025. The healthcare company's shares rallied on the back of strong growth prospects and continued analyst confidence, overshadowing a slight miss in revenue expectations.

In its Q2 2025 earnings report, Astrana Health revealed a 35% year-over-year increase in revenue, reaching $631.44 million. While this fell short of the $638.30 million consensus estimate from nine analysts, the company's growth trajectory remained impressive. The income from operations stood at $49.685 million, reflecting the company's ability to manage costs effectively in a challenging healthcare environment.

Several factors contributed to the stock's surge. Firstly, Astrana Health reiterated its full-year 2025 guidance, including the impact of its recently completed Prospect Health acquisition. This move is expected to enhance the company's growth prospects significantly. Secondly, despite the revenue miss, the company's adjusted EBITDA for Q2 came in at the higher end of its guidance, showcasing operational efficiency. Lastly, Wall Street maintains a bullish outlook on Astrana Health, with a median 12-month price target of $46.00, representing a potential upside of over 50% from recent trading levels. The current average analyst rating on the shares is "buy," with 8 out of 11 analysts recommending either "strong buy" or "buy."